DB
GBT

Dmitry Balyasny’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Dmitry Balyasny’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,151,518
Closed -$78.4M – 3574
2022
Q3 		$78.4M Buy
+1,151,518
New +$63.5M 0.24% 85
2022
Q1 		– Sell
-104,154
Closed -$3.05M – 3027
2021
Q4 		$3.05M Buy
+104,154
New +$3.23M 0.01% 1032
2019
Q2 		– Sell
-172,948
Closed -$9.15M – 1807
2019
Q1 		$9.15M Sell
172,948
-22,645
-12% -$1.11M 0.06% 411
2018
Q4 		$8.03M Buy
195,593
+188,991
+2,863% +$7.08M 0.06% 402
2018
Q3 		$251K Sell
6,602
-41,972
-86% -$1.86M ﹤0.01% 1544
2018
Q2 		$2.2M Sell
48,574
-44,146
-48% -$2.01M 0.01% 904
2018
Q1 		$4.48M Buy
+92,720
New +$5.17M 0.02% 742
2017
Q4 		– Sell
-8,677
Closed -$269K – 2405
2017
Q3 		$269K Buy
+8,677
New +$244K ﹤0.01% 1581
2016
Q2 		– Sell
-30,300
Closed -$481K – 1527
2016
Q1 		$481K Buy
+30,300
New +$538K ﹤0.01% 898

Other funds holding GBT

BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Dmitry Balyasny's GBT Position: Q4 2022 in Review

Dmitry Balyasny sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 1,151,518 shares — an estimated $78.4M sold.

Dmitry Balyasny first reported a position in GBT in Q1 2016 and held it in 9 quarters. The position peaked at $78.4M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • Dmitry Balyasny reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Dmitry Balyasny sold 1,151,518 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $78.4M.
  • Dmitry Balyasny first reported a position in Global Blood Therapeutics, Inc. in Q1 2016 and held it in 9 quarters.
  • Dmitry Balyasny's Global Blood Therapeutics, Inc. position peaked at $78.4M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.